{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:39:53Z","timestamp":1788824393632,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40257-024-00909-5","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T14:11:09Z","timestamp":1736172669000},"page":"275-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2\u201311\u00a0Years with Moderate to Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-1605","authenticated-orcid":false,"given":"Linda","family":"Stein Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-1856","authenticated-orcid":false,"given":"Seth","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-7130","authenticated-orcid":false,"given":"Andrea","family":"Zaenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7215-9346","authenticated-orcid":false,"given":"YuTzu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6416-0773","authenticated-orcid":false,"given":"Brett","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-883X","authenticated-orcid":false,"given":"Howard","family":"Kallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"10247","key":"909_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"issue":"2","key":"909_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2310\/6620.2007.06034","volume":"18","author":"JM Hanifin","year":"2007","unstructured":"Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82\u201391. https:\/\/doi.org\/10.2310\/6620.2007.06034.","journal-title":"Dermatitis"},{"issue":"4","key":"909_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328.e2. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"909_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.029.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"909_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.\u00a0https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"909_CR6","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260.","journal-title":"Front Immunol"},{"issue":"1","key":"909_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"7","key":"909_CR8","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/eji.201445303","volume":"45","author":"F Borriello","year":"2015","unstructured":"Borriello F, Longo M, Spinelli R, Pecoraro A, Granata F, Staiano RI, et al. IL-3 synergises with basophil-derived IL-4 and IL-13 to promote the alternative activation of human monocytes. Eur J Immunol. 2015;45(7):2042\u201351. https:\/\/doi.org\/10.1002\/eji.201445303.","journal-title":"Eur J Immunol"},{"issue":"3","key":"909_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","volume":"126","author":"BE Kim","year":"2008","unstructured":"Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332\u20137. https:\/\/doi.org\/10.1016\/j.clim.2007.11.006.","journal-title":"Clin Immunol"},{"issue":"15","key":"909_CR10","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317. https:\/\/doi.org\/10.1182\/blood-2009-04-214957.","journal-title":"Blood"},{"key":"909_CR11","unstructured":"Opzelura\u2122 (ruxolitinib cream). Full Prescribing Information, Incyte Corporation, Wilmington, DE, 2023."},{"issue":"4","key":"909_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"909_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060.","journal-title":"J Am Acad Dermatol"},{"key":"909_CR14","unstructured":"Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, et al. A phase 3 study of ruxolitinib cream in children aged 2\u2013<12 years with atopic dermatitis (TRuE-AD3): 8-week analysis. 32nd European Academy of Dermatology and Venereology (EADV) Congress; 2023 October 11\u201314; Berlin, Germany."},{"issue":"3","key":"909_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","volume":"23","author":"R Bissonnette","year":"2022","unstructured":"Bissonnette R, Call RS, Raoof T, Zhu Z, Yeleswaram S, Gong X, Lee M. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355\u201364. https:\/\/doi.org\/10.1007\/s40257-022-00690-3.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"909_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/2168479014539157","volume":"49","author":"ED Bashaw","year":"2015","unstructured":"Bashaw ED, Tran DC, Shukla CG, Liu X. Maximal usage trial: an overview of the design of systemic bioavailability trial for topical dermatological products. Ther Innov Regul Sci. 2015;49(1):108\u201315.\u00a0https:\/\/doi.org\/10.1177\/2168479014539157.","journal-title":"Ther Innov Regul Sci."},{"key":"909_CR17","unstructured":"ClinicalTrials.gov. Study of Ruxolitinib Cream in Children With Atopic Dermatitis. NCT05034822. 2021. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05034822. Accessed Apr 3 2024."},{"issue":"4","key":"909_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","volume":"22","author":"X Gong","year":"2021","unstructured":"Gong X, Chen X, Kuligowski ME, Liu X, Liu X, Cimino E, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies. Am J Clin Dermatol. 2021;22(4):555\u201366. https:\/\/doi.org\/10.1007\/s40257-021-00610-x.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"909_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quint\u00e1s-Cardama","year":"2011","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127\u201340. https:\/\/doi.org\/10.1038\/nrd3264.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"909_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181\u201392. https:\/\/doi.org\/10.1007\/s40257-018-0413-2.","journal-title":"Am J Clin Dermatol"},{"key":"909_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.0594","author":"AS Paller","year":"2024","unstructured":"Paller AS, Rangel SM, Chamlin SL, Hajek A, Phan S, Hogeling M, et al. Stigmatization and mental health impact of chronic pediatric skin disorders. JAMA Dermatol. 2024;160(6):621\u2013630. https:\/\/doi.org\/10.1001\/jamadermatol.2024.0594.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"909_CR22","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11136-020-02700-5","volume":"30","author":"AC Carle","year":"2021","unstructured":"Carle AC, Bevans KB, Tucker CA, Forrest CB. Using nationally representative percentiles to interpret PROMIS pediatric measures. Qual Life Res. 2021;30(4):997\u20131004. https:\/\/doi.org\/10.1007\/s11136-020-02700-5.","journal-title":"Qual Life Res"},{"issue":"9","key":"909_CR23","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s11136-020-02513-6","volume":"29","author":"CM Mann","year":"2020","unstructured":"Mann CM, Schanberg LE, Wang M, von Scheven E, Lucas N, Hernandez A, et al. Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. Qual Life Res. 2020;29(9):2573\u201384. https:\/\/doi.org\/10.1007\/s11136-020-02513-6.","journal-title":"Qual Life Res"},{"key":"909_CR24","unstructured":"Smith SH, Volkova A, Estrada Y, Correa da Rosa J, Saint-Cyr Proulx E, Nawaz H, et al. Effect of ruxolitinib cream on biomarkers of atopic dermatitis. 5th Inflammatory Skin Disease Summit (ISDS); 2023 November 15\u201318; Vienna, Austria."},{"issue":"1","key":"909_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2019.05.102","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Patel KR, Rastogi S, Singam V, Vakharia PP, Chopra R, Silverberg JI. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(1):62\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.102.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"909_CR26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","volume":"130","author":"DYM Leung","year":"2023","unstructured":"Leung DYM, Paller AS, Zaenglein AL, Tom WL, Ong PY, Venturanza ME, et al. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130(4):500\u2013507. https:\/\/doi.org\/10.1016\/j.anai.2022.12.033. (e3).","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00909-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:26:39Z","timestamp":1740385599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00909-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00909-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"17 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Incyte Corporation (Wilmington, DE, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LSG has served as an investigator, advisor, and\/or speaker for AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Ortho Dermatologics, Pfizer, Regeneron, and Sanofi. RB is an advisory board member, consultant, speaker, and\/or investigator for and received honoraria and\/or grants from AbbVie, Almirall, Amgen, AnaptysBio, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Escalier, Janssen, Kyowa Kirin, LEO Pharma, Nimbus, Pfizer, Regeneron, Sienna, and UCB. He is also an employee and shareholder of Innovaderm Research. SF has received honoraria, clinical research grants, or fees as a consultant, speaker, advisory board member, and\/or investigator for AbbVie, Aclaris Therapeutics, Asana BioSciences, AstraZeneca, Athenex, Celgene Corporation, Cutanea Life Sciences, Eli Lilly, Incyte Corporation, Innovaderm Research, Novartis, Pfizer, Promius Pharma, Regeneron, UCB, Valeant Pharmaceuticals North America, and XBiotech. AZ has served as an investigator and\/or consultant for AbbVie, Biofrontera, Dermavant, Galderma, Incyte, and UCB. YK, BA, XC, and HK are employees and shareholders of Incyte Corporation. ASP has served as an investigator, consultant, or data safety monitoring board member for AbbVie, Abeona, Apogee, Applied Pharma Research, Arcutis, Aslan, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, Johnson and Johnson, Krystal Biotech, LEO, Mitsubishi Tanabe, Nektar, Primus, Procter and Gamble, Regeneron, Sanofi, Seanergy, TWI Biotech, and UCB. ASP is an editorial board member of the American Journal of Clinical Dermatology. ASP was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except Phase 1 studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (e.g., US, EU, JPN). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte\u2019s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"This study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by the Advarra Institutional Review Board (Columbia, MD, USA).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent\/assent was provided by all patients before enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"LSG, RB, BA, HK, and ASP made substantial contributions to the conception and design of the work. LSG, RB, SF, AZ, and ASP all made substantial contributions to the acquisition of data. YK and XC made substantial contributions to the analysis of the data; all authors made substantial contributions to the interpretation of data; all authors drafted the work and revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}